ImmunityBio Inc IBRX
NASDAQ · United States · Health Technology
$9.20-0.24 (-2.60%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Vanguard’s six reporting entities collectively held 36.48 million shares after adding a net 2.43 million during Q2.
ImmunityBio stock climbed over the $10 mark for the first time since March this year.
The GA-Courtenay Special Situations Fund is an investment fund managed by Green Ash Partners. The fund focuses on special situations and high-growth equities. You can download the July letter here. The fund reported a 13.8% decline in July, bringing its year-to-date performance to -10.0%. The fund attributed the decline to an unusual liquidity-driven dislocation across […]
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.